CRO Europital opens new UK site in response to urgent demand
![](/46/pdcnewsitem/08/45/26/pexels-pixabay-40568.png)
The company will target working with small and medium biotechs who require a science-driven, rather than a volume-driven partner.
Europital – a global provider of medical management services for clinical research and drug development – is opening a UK site to further expand its services to the UK biotech industry. The company is already working with a number of UK partners and is forecasting compound growth nearly 30% of the next 3 years.
The Europital site will expand its operational team over the next few months and will target working with small and medium biotechs to design and execute projects, particularly for First in Man, Phase I and Phase II clinical studies.
The clinical research organization (CRO), which already partners with several biotechs in the UK, says it has seen a "clear gap in the market" for small innovators looking for a science focussed CRO that can provide detailed knowledge and therapeutic experience.
Gaining access to senior medical CRO expertise can be extremely challenging for the smaller innovators. The company says they can provide a medical department with real-world trial experience to implement study design and protocols.
Europital is planning to quickly expand its offering and will focus on providing expertise to partners in complex oncology indications, inflammatory diseases, immunology and infectious diseases studies.
The UK site opening will be used to leverage the company’s Phase III experience with clinical studies directly conducted at UK investigative sites.
Dr Mohamed El Malt, CEO and Chief Medical Officer of Europital said that much of the UK's cutting-edge innovation lies with smaller companies and spin outs and it is these organizations that really need the help of a science-driven CRO rather than that of a volume-driven large CRO that "usually won’t give the study the attention it needs".
"You often hear ‘follow the molecule’ in CRO circles. What we are doing is following the innovator and looking at where we can best help partners advanced targets more quickly through clinical trials," said Dr El Malt.
The company says that the shortage of senior experience in the market - primarily due to the number of trials currently underway - has resulted in almost 100% repreat business.
This development also opens up direct access to UK investigational sites for Europital's existing European and North American partners with Phase IIIstudies.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance